Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/9801
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae
Author: Black, P.
Blasi, F.
Jenkins, C.
Scicchitano, R.
Mills, G.
Rubinfeld, A.
Ruffin, R.
Mullins, P.
Dangain, J.
Cooper, B.
David, D.
Allegra, L.
Citation: American Journal of Respiratory and Critical Care Medicine, 2001; 164(4):536-541
Publisher: Amer Lung Assoc
Issue Date: 2001
ISSN: 1073-449X
1535-4970
Statement of
Responsibility: 
Peter N. Black, Francesco Blasi, Christine R. Jenkins, Raffaele Scicchitano, Graham D. Mills, Abraham R. Rubinfeld, Richard E. Ruffin, Peter R. Mullins, Josette Dangain, Bruce C. Cooper, Denise Bem David, And Luigi Allegra
Abstract: Chlamydia pneumoniae and the severity of asthma, and uncontrolled observations have suggested that treatment with antibiotics active against C. pneumoniae leads to an improvement in asthma control. We studied the effect of roxithromycin in subjects with asthma and immunoglobulin G (IgG) antibodies to C. pneumoniae > 1:64 and/or IgA antibodies > 1:16. A total of 232 subjects, from Australia, New Zealand, Italy, or Argentina, were randomized to 6 wk of treatment with roxithromycin 150 mg twice a day or placebo. At the end of 6 wk, the increase from baseline in evening peak expiratory flow (PEF) was 15 L/min with roxithromycin and 3 L/min with placebo (p 0.02). With morning PEF, the increase was 14 L/min with roxithromycin and 8 L/min with placebo (NS). In the Australasian population, the increase in morning PEF was 18 L/min and 4 L/min, respectively (p = 0.04). At 3 mo and 6 mo after the end of treatment, differences between the two groups were smaller and not significant. Six weeks of treatment with roxithromycin led to improvements in asthma control but the benefit was not sustained. Further studies are necessary to determine whether the lack of sustained benefit is due to failure to eradicate C. pneumoniae.
Keywords: Humans; Chlamydophila pneumoniae; Chlamydophila Infections; Pneumonia, Bacterial; Asthma; Chronic Disease; Roxithromycin; Immunoglobulin G; Antibodies, Bacterial; Anti-Bacterial Agents; Peak Expiratory Flow Rate; Forced Expiratory Volume; Treatment Outcome; Severity of Illness Index; Follow-Up Studies; Double-Blind Method; Time Factors; Adult; Middle Aged; Female; Male
Description: Copyright © 2001 American Thoracic Society
RMID: 0020011105
DOI: 10.1164/ajrccm.164.4.2011040
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.